Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017

Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.  The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 6 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson's Disease, Presbyopia, Rett Syndrome and Sialorrhoea. 

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
AstraZeneca Plc
Heptares Therapeutics Ltd
Karuna Pharmaceuticals Inc
NeuroHealing Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ANAVEX-273 + donepezil hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline tartrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropicamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6000918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers
Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer's disease Patients
Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimers Disease
Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model
Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson's Disease
Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
Jul 12, 2016: Anavex to Present at the Alzheimer's Association International Conference (AAIC) 2016
Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Anavex Life Sciences Corp, H1 2017
Pipeline by AstraZeneca Plc, H1 2017
Pipeline by Heptares Therapeutics Ltd, H1 2017
Pipeline by Karuna Pharmaceuticals Inc, H1 2017
Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Dormant Projects, H1 2017
Discontinued Products, H1 2017